Navigation Links
Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients
Date:5/31/2009

The results of these studies will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009

COLUMBIA, Md., May 31 /PRNewswire/ -- A study conducted at Westchester Medical Center in Valhalla, NY examined liver transplant recipients to determine whether the use of the ImmuKnow assay to guide immunosuppression therapy would reduce drug toxicity and drug-related adverse events.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090424/NE99362LOGO )

According to Dr. Patricia Sheiner, the lead investigator in this study, "Using ImmuKnow in liver transplant recipients may help minimize renal injury by providing a more individually-adjusted immunosuppression therapy." Dr. Sheiner added that, "ImmuKnow may lead to improved immunosuppression therapy management that benefits transplant patients by reducing adverse effects." In 20 patients, clinical decision-making during the management of immunosuppression therapy was based on ImmuKnow assay levels. In 32 other patients, changes in immunosuppression therapy were based on immunosuppressive drug levels. Although it did not reach statistical significance, the use of the ImmuKnow assay resulted in substantially lower mean serum creatinine levels at 5 months.

In a study to determine whether ImmuKnow can guide adjustment of immunosuppressive medications to lower risks of infection and/or graft loss, Dr. Abubakr A. Imam and co-investigators at the Akron Children's Hospital in Ohio conducted a retrospective study to assess the role of the ImmuKnow assay in viral surveillance and immune function monitoring in 35 pediatric renal transplant patients.

"Among the 5 patients who became positive for EBV or BK virus," explained Dr. Imam, "each event was preceded by a deviation in baseline ImmuKnow status. Immunosuppression was adjusted in each case, accordingly, without evidence of graft loss or clinical symptoms." He concluded by saying, "Viral surveillance together with ImmuKnow can be useful to prevent infection or organ rejection by tailoring immunosuppressive therapy." For each patient, viral studies and ImmuKnow results were routinely obtained and immunosuppressive drug dosing was adjusted based on positive viral studies using ImmuKnow results as an adjunct tool.

In a related study, researchers at the University of North Carolina at Chapel Hill and Ohio State University prospectively studied the use of the ImmuKnow assay together with various viral markers in 93 renal transplant recipients. Lead study investigator, Dr. Kenneth A. Andreoni, summarized the results of the study by saying, "We collected ImmuKnow data along with viral monitoring. From our data, we feel we may be able to prevent some viral infections by decreasing immunosuppression when ImmuKnow assay values are <100ng/ml or when post-transplant baseline ImmuKnow values decrease by >50%." Among patients who developed elevated viral levels, the majority either displayed an ImmuKnow value <100ng/ml or >50% decrease in baseline ATP value. In several of these patients, low ImmuKnow results led directly to immunosuppression medication decreases and subsequent increases in ImmuKnow with no infections or rejections.

The use of the ImmuKnow assay as described in these studies has not been cleared by the U.S. Food & Drug Administration.

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient.

About Cylex, Inc.

Cylex is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinicians to simply and reproducibly assess CMI. The Company is based in Columbia, MD USA. http://www.cylex.net


'/>"/>
SOURCE Cylex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
2. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
3. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
4. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
5. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
8. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
9. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
10. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
11. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of ... In his new role, Marziani will lead the company,s business development and sales team, ... outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... , May 24, 2016 Dutch surgeons ... best practices around the world and treat patients on a global ... Africa , Asia and the US ... with instant messaging and networking in a totally secure environment. ... in a war zone working together with a surgeon at Harvard ...
(Date:5/23/2016)... , May 23, 2016 ... titled, " Exocrine Pancreatic Insufficiency Market - Global Industry ... 2023 ." According to the report, the exocrine pancreatic ... of 8.3% from 2015 to 2023 to reach US$2.85 ... is a condition characterized by the deficiency of the ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our ... PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce Meghan ... football front we have Brian Quick, wide receiver for Los Angeles who was a ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... to provide strategic sales leadership and to further develop their rapidly expanding portfolio ... in Business Administration with a concentration in Marketing and an M.B.A. with concentration ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... . With over 20 years of experience in leading technology and human resources ... years of university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... safety efforts for several years, and the efforts have paid off. Since ... include new standards of care to enhance perioperative patient experiences and reduce costly ...
(Date:5/26/2016)... ... , ... May 2016 – Lips may be a central feature on our ... numbers of clients now ask about lip plumping and primping techniques and want tips ... Advanced Dermatology P.C. , The trend is a national one, with 2.4 ...
Breaking Medicine News(10 mins):